PFEIFFER GARY M sold $292K of DGX

PFEIFFER GARY M sold 1,203 shares of QUEST DIAGNOSTICS INC (DGX) at $243.00 ($0.29M total) on 2026-10-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · PFEIFFER GARY M
Published Oct 28, 2026, 10:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 10:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DGX
Bearish
high confidence
Mentioned
$DGX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DGXBearishLow
01

Why it matters

A director's sale, especially via a 10b5‑1 plan, can be interpreted as a lack of confidence, prompting short‑term price pressure.

02

Market read

The filing provides fresh, primary‑source data on insider activity, offering a modest trading signal for DGX.

03

What to watch

Potential upcoming earnings or strategic announcements could offset the negative signal from the sale.

Relevance 3/10Novelty 3/10Timing: today

Background

Form 4 filings disclose insider transactions and are used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$DGXBearishHigh confidence
Context

Director Gary M. Pfeiffer sold 1,203 shares of Quest Diagnostics for $292,329 via a 10b5-1 plan, reducing his holdings to 29,802 shares.

Expected impact

likely modest downward pressure as the market prices in the insider sale

Evidence & confidence

Form 4 filings are primary source disclosures; a director sale, even modest, can trigger short‑term selling pressure.

Market effects

Minimal impact on the healthcare diagnostics sector; the sale is company‑specific.

No notable regional effect; limited to investors tracking Quest Diagnostics.

Negligible on a global scale; only relevant to DGX shareholders.

Counterpoint

The sale may be routine under a pre‑arranged 10b5‑1 plan and not indicative of future performance.

Key entities

  • Quest Diagnostics Inc.

    Provider of diagnostic testing services, ticker DGX.

  • Gary M. Pfeiffer

    Director of Quest Diagnostics who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DGXLow

Quest Diagnostics Pays $13 Million to Settle Kickback Allegations Involving New York Giants Tickets

Quest Diagnostics will pay $13M to settle allegations of illegal kickbacks, including New York Giants tickets, to healthcare providers. The U.S. Attorney's Office claims the company violated the Anti-Kickback Statute from 2013 to 2022, offering perks in exchange for business referrals. Quest denies wrongdoing but agreed to a settlement and a 5-year compliance agreement.

$DGXLow

Quest Diagnostics pays more than $13M to settle alleged kickback scheme, federal prosecutors say

Quest Diagnostics agreed to pay $13M to settle allegations of a kickback scheme involving gifts to hospital executives, including New York Giants game tickets, according to federal prosecutors. The scheme allegedly lasted from 2013 to 2022, with Quest billing government-funded medical plans. The company will also face five years of auditing. Quest reported $11B in 2025 revenue, up 7%.

$DGXLow

Quest Diagnostics pays $13M to settle kickback allegations involving NY Giants tickets

Quest Diagnostics agreed to pay $13M to settle allegations of providing illegal kickbacks, including NY Giants tickets, to healthcare providers for referrals, according to the U.S. Attorney’s Office of New Jersey. The settlement resolves claims of violating the Anti-Kickback Statute and submitting false claims to Medicare and Medicaid. Quest denies wrongdoing but agreed to the settlement to resolve the matter.

$DGXLow

Quest Diagnostics pays more than $13 million to settle allegations of illegal kickbacks involving Giants tickets, VIP events

Quest Diagnostics Inc. paid $13,014,576 plus interest to settle federal allegations of illegal kickbacks involving free New York Giants tickets and VIP events to induce patient referrals. The company violated the Anti-Kickback Statute and submitted false claims to Medicare and Medicaid programs, according to the U.S. Attorney’s Office. Quest also entered a five-year Corporate Integrity Agreement with HHS-OIG. Whistleblowers will receive nearly $2.5 million.

$LHMed

Labcorp, Quest urge RESULTS Act passage as lab payment cuts loom

Labcorp and Quest Diagnostics warn of revenue impacts from upcoming Medicare and Medicaid reimbursement cuts starting in 2027. Labcorp expects a $125 million hit, while Quest estimates a 1% revenue reduction in 2026. Both companies advocate for the passage of the RESULTS Act to reform the payment rate-setting process, citing concerns over patient access and lab viability.